Environmental Impact Acquisition Corporation approval obtained; GreenLight Biosciences set to begin trading under Nasdaq: GRNA on February 3, 2022 PR Newswire BOSTON, Feb. 2, 2022 BOSTON, Feb. 2...
GreenLight Biosciences and Germains Seed Technology Partner to Explore Development of World's First dsRNA Seed Treatment to Control Pests PR Newswire BOSTON, Jan. 31, 2022 BOSTON, Jan. 31, 2022...
ENVI Announces Quorum to Pass Business Combination With GreenLight Biosciences and Achievement of All Transaction Requirements Following the Redemption Deadline Upon consummation of the business...
ENVI and GreenLight Biosciences Announce Filing of Definitive Proxy Statement/Prospectus and the February 1st, 2022 Special Meeting to Approve Proposed Business Combination PR Newswire BOSTON...
GreenLight Biosciences (ENVI) partners with IAVI to accelerate COVID-19 vaccine trial in Africa - IAVI's extensive clinical trial experience will be combined with GreenLight COVID-19 vaccine...
Serum Life Sciences invests in RNA biotech GreenLight by joining expanded financing for Environmental Impact Acquisition Corp. PR Newswire BOSTON, Nov. 23, 2021 BOSTON, Nov. 23, 2021 /PRNewswire/...
Greenlight Biosciences (ENVI) Adds Two World-Renowned Scientists To Its Scientific Advisory Board PR Newswire BOSTON, Nov. 4, 2021 BOSTON, Nov. 4, 2021 /PRNewswire/ -- GreenLight Biosciences is...
GreenLight Biosciences opens RNA production facility for the next generation of agricultural products PR Newswire ROCHESTER, N.Y., Sept. 22, 2021 ROCHESTER, N.Y., Sept. 22, 2021 /PRNewswire/...
New York, NY , March 03, 2021 (GLOBE NEWSWIRE) -- Environmental Impact Acquisition Corp. (the “Company”) announced today that, commencing March 8, 2021, holders of the 20,700,000 units sold in...
NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Environmental Impact Acquisition Corp. (the “Company”), a newly organized blank check company formed for the purpose of effecting a merger, capital...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales